FDA Approves First-Line Treatment for NSCLC with PD-L1 Biomarker
April 12, 2019
On April 11, the U.S. Food and Drug Administration approved pembrolizumab (KEYTRUDA) as a first-line treatment for patients with advanced NSCLC who have a score of 1% or higher on the PD-L1 biomarker test. The approval was based on KEYNOTE-042 trial which demonstrated statistically significant OS improvements for those randomized to pembrolizumab compared with chemotherapy.Click here to read the full press release.
Lung cancer questions? Contact our free HelpLine at support@go2.org or 1-800-298-2436.